PVigilant Health

Home
United Arab Emirates
Dubai
PVigilant Health

PVigilant Health was established to provide support, solutions and consultations on Pharmacovigilance

04/01/2026

Rethinking Moxifloxacin Safety 🏥
Is your patient at risk for Drug‐Induced Liver Injury?

New data suggests that systematic risk stratification is essential for hospitalized patients on Moxifloxacin.

Who is at higher risk?

📊 Biomarkers: Patients with low albumin or elevated ALP.
🧬 Comorbidities: Those with existing fatty liver or liver injury.
💊 Polypharmacy: Patients also taking traditional Chinese medicine or respiratory medications.

Find out more here ⬇️
https://www.researchgate.net/publication/399236116_Drug-Induced_Liver_Injury_Associated_With_Moxifloxacin_A_Pharmacovigilance_Analysis_of_the_FDA_Adverse_Event_Reporting_System_and_a_Real-World_Retrospective_Study

01/01/2026

⏳️ The world of medicine is fast-paced, but our vigilance is faster. In 2026, PVigilant Health continues to bridge the gap between pharmaceutical innovation and patient security.

Happy New Year to our global healthcare community! 🌟

31/12/2025

🔬 The FDA landscape is evolving fast! To keep our PVigilant Health community informed, we’ve summarized the most notable novel drug approvals of 2025.

Whether it's the first-in-class antibiotic Blujepa or the innovative pain-reliever Journavx, these drugs are set to change lives.

Which of these breakthroughs do you think will have the biggest impact on clinical practice this year? Let us know in the comments! 💬👇

Save this post for your professional reference and share it with your colleagues in the medical field! 🛡️✨

29/12/2025

📢 Safety Alert: Is Metoclopramide still in your pediatric toolkit?

Attention Healthcare Professionals,
Patient safety is the core of pharmacovigilance. Recent data and regulatory updates have tightened the restrictions on Metoclopramide use in children under 10 due to serious neurological risks.

🛡️ At PVigilant Health, we believe reporting is the first step to safety. Help us build a safer future by reporting any suspected ADRs.

25/12/2025

Is it time to update our clinical monitoring protocols for Itraconazole? 🤔

While ITZ remains vital for systemic and cutaneous fungal infections, a recent large-scale pharmacovigilance study involving over 6 million FAERS reports has shed new light on its safety profile.

What’s New?!
Find out more here ⬇️
https://www.researchgate.net/publication/398958592_Itraconazole-associated_adverse_events_in_fungal_infections_a_study_of_a_large_real-world_sample_based_on_the_FAERS_database_2019-2024

PVigilant_Health

23/12/2025

We are proud to announce that our Managing Director, Dr. Ahmed Hegazy, will be serving as the Co-Chair for the 5th Edition Drug Safety Symposium 2026 – Middle East Chapter. Dr. Hegazy will lead a deep dive into the practicalities of Sponsor–CRO partnerships, sharing insights on:

▪️ Defining clear roles and responsibilities.
▪️ Implementing effective oversight strategies.
▪️ Avoiding the common pitfalls identified during inspections.

Whether you are a Sponsor or a CRO, join us to learn what truly works in real-world PV operations.

📅 Jan 21st-22nd | Grand Mercure Dubai City
🔗 Don’t miss this opportunity to refine your oversight and ensure compliance: https://www.drugsafetysymposium.com/reach-out/

20/12/2025

⚠️ ATTENTION PRESCRIBERS: Are you accidentally double-dosing NSAIDs?

We frequently encounter a classic prescription pattern: a potent NSAID paired with a Skeletal Muscle Relaxant (SMR). While the intent is maximum pain relief, a critical pharmacological oversight often occurs when the relaxant itself contains a hidden NSAID.

Inside this guide:
🕵️ How to spot "Hidden" NSAIDs in common relaxants.
📉 Why double-dosing provides zero extra benefit but double the risk.

Expertise isn't in how many drugs we prescribe, but in how safely we use them.

Let’s protect our patients' kidneys and stomachs while we treat their joints.

17/12/2025

Stop chasing noise. Start finding signals. 🛑💊

Disproportionality analysis is a staple of , but it’s often plagued by bias. How do we move from simple association to meaningful causal inference?

Find out more here ⬇️
https://www.researchgate.net/publication/398607996_Causal_Inference_Tools_for_Pharmacovigilance_Using_Causal_Graphs_to_Identify_and_Address_Biases_in_Disproportionality_Analysis

14/12/2025

⚠️ Recognizing Withdrawal Pruritus with Cetirizine & Levocetirizine

⚠️ Attention: The US Food and Drug Administration (FDA) has issued a crucial safety warning regarding the long-term use of Cetirizine and Levocetirizine (second-generation H1-antihistamines).

This advisory highlights a potentially debilitating adverse effect: Severe Rebound Pruritus following abrupt cessation after chronic use.

Protecting patients from an iatrogenic symptom is a priority.

Knowledge = Life 🌱

▶️ Follow PVIGILANT Health to receive the latest updates. Please help us extend this crucial message by sharing this post.

11/12/2025

🛑 CRITICAL PRACTICE ALERT: Why Sublingual Captopril (Capoten) Must Be Abandoned in Hypertensive Urgency

To Our Colleagues: Physicians and Pharmacists,

For years, the use of sublingual Captopril or oral Furosemide (Lasix) for Hypertensive Urgency has persisted. It is time to recognize this as one of the most dangerous and outdated practices in contemporary medicine.

Why? Sublingual Captopril causes unpredictable and sudden BP drops, risking **Cerebral Hypoperfusion, Stroke, and Type 2 MI.**

Treating Hypertensive Urgency with sublingual Captopril is not "First Aid"—it is a **Risk Multiplier** that threatens to precipitate the very complications we aim to prevent. It is **Not Evidence-Based.**

Knowledge = Life 🌱

▶️ Follow PVIGILANT Health to receive the latest updates. Please help us extend this crucial message by sharing this post.

08/12/2025

🚨 Safety Alert: Comprehensive Re-evaluation of Pipazethate in Pediatric Cough Management

Global trends are accelerating to restrict or cease the use of Pipazethate (a non-opioid antitussive) in children, driven by recent Pharmacovigilance reports and safety concerns worldwide.

📍Why the Restriction?

▪️High Overdose Risk: The substance features a narrow therapeutic index, significantly elevating the risk of accidental pediatric toxicity.

▪️Serious Toxicity Risks: Documented complications include severe CNS Depression, Seizures, and cardiac rate abnormalities.

▪️High-Risk Formulations Withdrawn: Globally, formulations difficult to dose accurately in children, such as drops and suppositories, are being withdrawn.

📍The Mandatory Directive:
Pipazethate is now strictly contraindicated for use in children under 4 years of age.

📍Shifting to Evidence-Based Practice:
The global consensus confirms that most antitussives for children offer marginal benefit versus high potential for harm.

📍Recommendation:
Focus must be placed on Causative Treatment (addressing the underlying etiology) and prioritizing safe, non-pharmacological measures (such as hydration, saline rinses, and honey after age one) as the first line of defense.

Knowledge = Life 🌱

▶️ Follow PVIGILANT Health to receive the latest updates. Please help us extend this crucial message by sharing this post.

04/12/2025

🩺 Clinical Guidance for Healthcare Professionals: Managing the Ciprofloxacin and Tizanidine Interaction
Given the severity of this drug-drug interaction, this combination must be strictly avoided.

Knowledge = Life 🌱

▶️ Follow PVIGILANT Health to receive the latest updates. Please help us extend this crucial message by sharing this post.

Address

Dubai

Website

http://www.pvigilant.com/

Alerts

Be the first to know and let us send you an email when PVigilant Health posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to PVigilant Health:

Shortcuts

Want your practice to be the top-listed Clinic in Dubai?